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Activation-induced cytidine deaminase (AID) 
is a cytidine deaminase thought to function 
  directly as a DNA mutator initiating somatic 
hypermutation and class switch recombination 
(CSR) of Ig genes. In addition to this role in 
producing antibody diversifi  cation within the 
vertebrate adaptive immune system, AID also 
mediates a form of host response against viral 
infection. Specifi  cally, AID is induced in primary 
B cells in response to infection by a transforming 
retrovirus, Abelson murine leukemia retrovirus 
(Ab-MLV). As a result of AID induction, the 
proliferation of infected host cells is signifi  cantly 
restricted both in vitro and in vivo. Therefore, 
in addition to its roles in somatic hypermutation 
and CSR, AID is active in the innate antiviral 
response and serves to limit the proliferation of 
tumors of viral etiology.
A growing body of evidence indicates that 
AID functions directly as a DNA mutator to 
  initiate Ig diversifi  cation. At the same time, in-
appropriate or ectopic expression of AID can 
lead to genomic instability (1, 2). It is therefore 
not surprising that AID needs to be tightly reg-
ulated at several levels. AID transcription is 
controlled by the synergistic action of several 
transcription factors, four of which have been 
identifi  ed: E47 (3), STAT6, NF-κB (4), and 
Pax5 (5). All of these are necessary, but none is 
suffi   cient to activate AID expression; thus, it is 
likely that additional regulators of AID expres-
sion remain to be identifi  ed. AID activity is 
also controlled by posttranslational modifi  ca-
tions (e.g., phosphorylation; references 6–9) 
and by subcellular localization (most AID is cy-
toplasmic although only the nuclear fraction 
appears to have DNA deamination activity; 
references 10–12).
AID induction is also part of the host re-
sponse to infection by hepatitis C virus (13) 
and by herpes EBV, which maintains AID 
  expression by latent membrane protein-1 sig-
naling during the establishment of latency (14) 
until later stages of the EBV growth program 
down-regulate AID expression to unleash B 
cell proliferation (15). To understand how dif-
ferent viruses induce the AID host response, 
we asked whether AID expression during viral 
infection involved signaling by the two main 
antiviral pathways, namely the interferon path-
way and the Toll-like receptor (TLR) pathway. 
Here we show that AID is not an interferon-
responsive gene: treatment of B cells with type 
I or type II interferon does not lead to AID 
  expression. Conversely, the AID response is not 
abrogated in IFN-αR–defi  cient or IFN-γ–defi  -
cient animals. In addition, even though TLR 
engagement leads to AID expression (this study 
and reference 16), the AID   response is not ab-
rogated in animals defi  cient in TLR signaling 
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(e.g., MyD88−/− or MyD88−/−Trif−/− mice). Our results 
strongly suggest that neither of the two main antiviral path-
ways is required for the expression of virally induced AID.
We did fi   nd that NF-κB was required for the AID 
  response to Ab-MLV infection of bone marrow B cells. The 
AID gene contains two NF-κB binding sites, both of which 
are occupied during CSR (4). NF-κB (p50) defi  ciency 
  severely diminishes CSR both in vitro (this study) and in vivo 
(17, 18). Our data suggest a direct link between NF-κB acti-
vation and AID expression in infected B cells.
RESULTS AND DISCUSSION
AID up-regulation does not require intact 
interferon signaling
To determine the signaling cascade that induces AID expres-
sion in Ab-MLV–infected cells, we fi  rst asked whether it re-
quired the v-abl kinase, which is the single protein product 
made by the retrovirus and the cause of transformation. We 
therefore infected cells with the highly related Moloney mu-
rine leukemia virus (Mo-MLV), which does not encode the 
v-abl kinase. We found that Mo-MLV infection of bone 
marrow cells resulted in AID up-regulation, although the in-
fected cells did not become transformed (Fig. 1 A).
Several other viruses induce or maintain AID expression 
upon infection (most prominently EBV [14, 19] and hepatitis 
C virus [13]), suggesting that these viruses activate a common 
signaling cascade culminating in AID expression in host cells. 
We fi  rst asked whether virally induced interferons signal AID 
expression but found that bone marrow B cells treated with 
recombinant type I or type II interferon (IFN-αβ and IFN-γ) 
did not express AID (unpublished data). Therefore, AID is 
not an interferon-inducible gene. Conversely, we found that 
bone marrow B cells from IFN-γ–defi  cient mice not only 
expressed AID as a consequence of infection but expressed 
higher amounts of AID at earlier time points after infection 
than wild-type congenic controls (Fig. 1 B and reference 20). 
B cells from IFN-α receptor–defi  cient animals (IFN-αR−/−) 
also expressed AID at wild-type levels upon infection with 
Ab-MLV. We conclude that viruses induce AID by a mecha-
nism that does not depend on signaling through the inter-
feron cascade.
AID is expressed in bone marrow B cells 
after ligation of endosomal TLRs
AID is expressed in B cells stimulated to class switch by treat-
ment with LPS, a ligand for the cell surface TLR4. We there-
fore investigated whether viruses induce AID expression in 
the host is by signaling through TLRs.
Although TLR4 has been linked to recognition of several 
viruses (21), the TLRs most commonly associated with viral 
recognition reside in the endosomes and bind viral nucleic 
acid. We therefore tested whether ligation of endosomal TLRs 
would induce AID expression. We found that stimulation of 
bone marrow cells with CpG-containing single strand DNA 
(a ligand for TLR9), resulted in AID expression within 24 h 
(Fig. 2 A and reference 16). Transfection of bone marrow cells 
with synthetic double strand RNA (a ligand for TLR3) also 
induced AID expression, albeit with slower kinetics (Fig. 2 B). 
We conclude that, not only TRL4, but also two endosomal 
TLRs can lead to induction of AID expression in B cells.
Abrogation of TLR signaling does not affect virally 
induced AID expression
Most TLRs signal through the adaptor molecule MyD88, 
with the exception of TLR3, which utilizes Trif (22). We 
Figure 1.  AID up-regulation does not require intact IFN signaling. 
(A) Mo-MLV infection of mouse bone marrow results in AID upregulation. 
CD79b expression is a loading control for the RT-PCR reaction. (B) IFN-γ 
and IFN-αR–defi  cient bone marrow cells induce AID expression upon 
viral infection.
Figure 2.  AID is up-regulated in bone marrow B cells after ligation 
of endosomal TLRs. (A) AID expression after transfection of BM cells 
with CpG for 24 h. (B) Time-course of AID expression after transfection 
of BM cells with double strand RNA.JEM VOL. 204, February 19, 2007  261
BRIEF DEFINITIVE REPORT
therefore asked whether Ab-MLV could activate the AID 
response in B cells from mice defi  cient in one (MyD88−/−) 
or both (MyD88−/−Trif−/−) of these adaptors. Surprisingly, 
we found that AID was still induced in B cells defi  cient in 
TLR signaling (Fig. 3 A). Furthermore, Ab-MLV could 
transform TLR signaling–defi  cient B cells with effi   ciencies 
indistinguishable from those seen in congenic wild-type con-
trols (Fig. 3 B). Finally, MyD88-defi  cient mice were indis-
tinguishable from congenic wild-type controls in their ability 
to up-regulate Rae-1 ligands (a hallmark of the AID host 
  response to Ab-MLV infection; unpublished data).
In mice defi  cient in TLR signaling, B cells fail to properly 
respond to immunization either with T cell–dependent or 
T cell–independent antigens (23). However, these defects are 
attenuated when such B cells are activated in vitro: B cells 
from MyD88−/− mice can switch from IgM to IgG2a after 
stimulation with CD40 and IL-4 to levels similar to those seen 
in wild-type B cells (24 and unpublished data). To   investigate 
the possibility that the AID response defect in MyD88−/− 
B cells is only evident in vivo, we monitored   disease progression 
in mice engrafted with either infected wild-type B cells or 
  infected MyD88-defi  cient B cells. We found that mice receiv-
ing infected wild-type bone marrow succumbed to Abelson 
disease with kinetics that were indistinguishable from those 
of mice receiving infected MyD88-defi  cient bone marrow 
(Fig. 3 C). We conclude that the AID response to viral infec-
tion does not depend on the TLR   signaling pathway in vitro 
or in vivo. In contrast, AID-  mediated adaptive immune re-
sponses appear to require an intact TLR signaling pathway, 
suggesting distinct pathways for AID expression in adaptive 
and innate immune responses (23, 24).
NF-𝗋B is required for host expression 
of AID upon viral infection
Several known stimuli such as CD40 ligation, TLR ligation, 
cytokine stimulation, and now a component of viral infec-
tion induce AID expression in B cells. We have shown that 
the signaling pathways used by viral infection to induce AID 
expression in B cells are not the ones which induce Ig diver-
sifi  cation (e.g., TLR4 ligation). Therefore, the pathways 
controlling AID transcription must converge in common 
  elements further downstream.
NF-κB is required for the Ig diversifi  cation program (18) 
and can be activated by several overlapping though distinct 
signaling pathways, many of which are activated by viral in-
fection (25). To determine whether virally induced AID ex-
pression requires NF-κB, we used Ab-MLV to infect bone 
marrow cells from mice defi  cient in the p50 subunit of the 
NF-κB heterodimer. We found that such NF- κB–defi  cient 
B cells were completely unable to up-regulate AID expres-
sion (Fig. 4 A). In addition, such cells were more susceptible 
to viral transformation (26 and unpublished data). Thus, the 
host response of NF-κB–defi  cient B cells to Ab-MLV infec-
tion and transformation closely parallels the one reported for 
AID-defi  cient B cells (20), suggesting a genetic link between 
the two.
NF-κB is necessary for AID-mediated Ig diversifi  cation 
in vivo (17). To address the role of NF-κB in Ig diversifi  ca-
tion in vitro, we stimulated cells to undergo CSR. Using two 
Figure 3.  Abrogation of TLR signaling does not diminish the 
  expression of virally induced AID. (A) Bone marrow cells from MyD88−/− 
and MyD88−/−Trif−/− mice induce AID expression upon infection with 
Ab-MLV. (B) B cells defi  cient in TLR signaling are susceptible to transfor-
mation by Ab-MLV. (C) Mice defi  cient in MyD88 are as susceptible as their 
wild-type counterparts to death after Ab-MLV infection.262  VIRAL ACTIVATION OF AID EXPRESSION REQUIRES NF-κB | Gourzi et al.
diff  erent stimulation protocols, we found that CSR was dras-
tically diminished in NF-κB–defi  cient B cells compared with 
congenic controls (Fig. 4 B). NF-κB is thought to regulate 
recombination to specifi  c Ig isotypes (18, 27) but has also 
been reported to directly modulate AID expression levels by 
binding and activating the AID promoter (4). Indeed, we 
found that NF-κB is necessary for optimal AID expression in 
splenic B cells stimulated to undergo CSR: NF-κB–defi  cient 
cells stimulated with CD40 and IL-4 or LPS and IL-4 showed 
a  substantial reduction in AID expression compared with 
wild-type controls (approximately a 10-fold reduction; Fig. 4 C 
and unpublished data). Collectively, these data suggest that 
NF-κB directly modulates AID gene transcription both 
during CSR and in the context of viral infection.
NF-𝗋B–p50 is recruited to the mouse AID promoter 
to activate AID expression during infection by Ab-MLV
The human AID promoter contains two NF-κB binding 
sites, and nuclear extracts from human cell lines that are 
stimulated to express AID can supershift oligonucleotides 
containing both sites. These in vitro experiments have sug-
gested that AID induction during CSR can be at least in 
part attributed to NF-κB (4). In contrast, a scan of the 
mouse AID promoter revealed a single NF-κB binding site 
(gaGGGActtgtc; capital letters refer to the core binding 
  sequence), corresponding to positions −1447 to −1434 
from the promoter. To directly confi  rm the link between 
viral AID induction and NF-κB activation, we asked whether 
this site was occupied in vivo by NF-κB–p50 after infection 
of B cells with Ab-MLV. Using chromatin immunoprecipi-
tation we found that the site was not occupied by NF-κB 
before infection (Fig. 5, day 0). However, the site was clearly 
bound by NF-κB at day 6 after infection (Fig. 5 A), a time 
point which coincides with the initial peak of AID expres-
sion (Figs. 3 and 4 and reference 20). Thus, our experiments 
demonstrate that, in vivo, NF-κB is recruited to the AID 
promoter during infection, with kinetics that parallel those 
of AID induction.
To demonstrate that NF-κB was not only recruited to, 
but could also transactivate the AID promoter, we infected 
bone marrow cells with Ab-MLV together with retroviruses 
carrying the AID promoter upstream of a luciferase reporter 
gene. Bone marrow cells infected with both Ab-MLV (ex-
pressing GFP) and with reporter virus (expressing RFP) were 
sorted on the basis of dual color expression and were analyzed 
for luciferase activity during infection. We could detect 
above-background luciferase activity but only in bone mar-
row cells coinfected with Ab-MLV and a retroviral con-
struct expressing luciferase under the control of the wild-type 
AID promoter (Fig. 5 B, wt κB Luc). In bone marrow cells 
Figure 4.  NF-𝗋B is required for expression of virally induced AID. 
(A) Bone marrow cells from NF-κB (p50)−/− mice cannot induce AID 
  expression upon infection with Ab-MLV. (B) NF-κB (p50)−/− splenic 
B cells are defective in CSR. Levels of CSR to IgG1 and IgG3 are shown 
72 h after stimulation with LPS and IL-4 or CD40 and IL-4. (C) NF-κB is 
required for optimal AID expression in switching B cells.JEM VOL. 204, February 19, 2007  263
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coinfected with Ab-MLV and a reporter construct in which 
the κB site was mutated (from gaGGGActtgtcc to gaAAAA-
cttgtc), luciferase expression was at baseline levels (Fig. 5 B, 
mut κB Luc). Thus, during viral infection, NF-κB binds and 
directly activates the AID promoter.
We have found that AID expression in response to viral 
infection and transformation requires NF-κB. Many antiviral 
cascades depend on distinct signaling components ultimately 
linked by NF-κB activation (25). Our results suggest that 
  viral induction of AID could use several signaling pathways 
that culminate in NF-κB activation, underscoring the versa-
tility of this host defense program.
MATERIALS AND METHODS
Cells and mice. Bone marrow cells were fl  ushed from the femurs and tibias 
of 5–8-wk-old mice and were grown in RPMI 1640 medium (Sigma-
  Aldrich) supplemented with 20% heat-inactivated FCS and 50 μM 2-mercapto-
ethanol (Sigma-Aldrich).
AID-defi  cient BALB/c Byj mice were obtained from M. Nussenzweig 
(The Rockefeller University). BALB/c Byj congenic controls and NF-κB–
defi  cient (p50−/−) C57BL/6 mice and IFN-γ–defi  cient C57BL/6 mice with 
appropriate congenic controls were obtained from The Jackson Laboratories. 
IFN-αR–defi  cient animals were a gift from David Levy (New York Uni-
versity Medical School, New York, NY), and MyD88-defi  cient mice and 
MyD88−/−Trif−/− mice along with congenic controls were a gift from 
S. Akira (via M. Nussenzweig). All animal research has been approved by the 
Rockefeller University Institutional Animal Care and Use Committee and 
was in compliance with the relevant federal guidelines.
Virus production and infections. Replication-defi  cient Ab-MLV was 
generated by transfection of 293T cells with pMIG–Ab-MLV retroviral con-
struct (a gift from Naomi Rosenberg, Tufts University School of Medicine, 
Boston, MA) and pCL packaging DNA (1:1 ratio) using Lipofectamine ac-
cording to the manufacturer’s protocol. Cells were cultured for 48 h, and the 
supernatant was fi  ltered through a 45-μm fi  lter and used as viral stock for 
infection of target cells.
Viral titers (infectious U/ml) were determined by counting the number 
of gfp+ cells that arose after infection of 3T3 cells with diff  erent dilutions of 
viral stock (multiplied by the dilution factor). For Ab-MLV infections, 2 × 
106 bone marrow cells were challenged for 2 h with a multiplicity of infec-
tion of 0.1.
Agarose transformation assay of bone marrow cells. 2 × 106 freshly 
prepared bone marrow cells from wild-type and congenic MyD88−/− and 
MyD88−/−Trif−/−-deficient mice were infected with equivalent titers of 
Ab-MLV for 4 h and seeded in 0.3% agar (United States Biological) contain-
ing RPMI–20% FCS–50 μM β-mercaptoethanol as described previously 
(28). Macroscopic colonies of transformed pre–B cells were counted 
between 9 and 12 d postinfection.
Tumorigenicity assay. Bone marrow cells were isolated from 5–6-
wk-old wild-type and congenic MyD88−/− mice and were infected for 
2 h with equivalent titers of replication-defi  cient Ab-MLV. After infection, 
the cells were washed once with PBS and were injected intravenously 
into lethally irradiated (800 rads) C57BL/6 8–10-wk-old female mice. Five 
recipients from each strain were injected with mock-infected bone marrow 
cells, and 20 recipients from each strain were injected with virus-infected 
bone marrow cells (1 million bone marrow cells/mouse). Mice were moni-
tored daily and analyzed soon after death by gross pathology, histology, 
and FACS.
Flow cytometry analysis. For the quantifi   cation of gfp+ B cells, we 
stained bone marrow cultures with anti–mouse B220 PE-conjugated 
  antibody (BD Biosciences). 7-amino actinomycin D was used for dead cell 
exclusion. FACS analysis was done on a FACSCalibur (Becton Dickinson) 
using Cellquest software (Becton Dickinson).
Figure 5.  NF-κB–p50 is recruited to the mouse AID promoter 
to directly activate AID expression during infection by Ab-MLV. 
(A) Occupancy of the NF-κB binding site present in the AID promoter is 
assessed by ChIP before (day 0) or during (day 6) infection of wild-type or 
NF-κB–p50–defi  cient animals. Occupancy of an NF-κB binding site 
present in the nearby APOBEC1 promoter was evaluated as a negative 
control. Threefold titrations are shown for input, anti–NF-κB immuno-
precipitation, and isotype control immunoprecipitation samples. (B) AID 
promoter activity in infected cells, in the presence or absence of the κB 
binding site. Bone marrow cells were coinfected with Ab-MLV and with a 
retroviral luciferase reporter construct containing either the wild-type κB 
site (wt κB Luc) or a mutated κB site (mut κB Luc). Promoter activity for 
each construct was measured in relative light units per μg of protein 
lysate. Results are means ± SD (n = 3).264  VIRAL ACTIVATION OF AID EXPRESSION REQUIRES NF-κB | Gourzi et al.
Quantitative (real-time) PCR. Bone marrow cells from 3–5-wk-old 
IFN-γ−/−, IFN-αR−/−, MyD88−/−, or MyD88−/−Trif−/− mice were 
  infected with Ab-MLV as described in earlier paragraphs. The cells were 
collected at diff  erent days postinfection and stained with anti–mouse B220 
PE-conjugated antibody. Cell sorting was performed on a FACSVantage 
(Becton Dickinson).
Total RNA was extracted from gfp+B220+ samples using Trizol (Invi-
trogen), according to the manufacturer’s instructions. RNA was treated with 
DNase I (Promega) at 1 U/μg. Reverse transcription was performed using 
Superscript III reverse transcriptase (Invitrogen) and random hexamers. 
Primers for AID amplifi  cation were as in reference 20. Results were normal-
ized to GAPDH.
Reagents. Phosphorothioate-stabilized CpG oligos (T  C  C  A  T  G  A  C  G  T  T  C-
C  T  G  A  T  G  C  T  ) and phosphorothioate-stabilized non-CpG oligos (G  C  T  T  G-
A  T  G  A  C  T  C  A  G  C  C  G  G  A  A  ) were purchased from MWG Biotech. Interferon 
α-A/D was purchased from Sigma-Aldrich. Double stranded poly(I):poly(C) 
was purchased from GE Healthcare.
NF-𝗋B chromatin immunoprecipitation (ChIP). Chromatin immuno-
precipitation (ChIP) assays were preformed using the ChIP kit from Upstate 
Biotech in conjunction with antibodies to NF-κB–p50 (also from Upstate 
Biotechnology) or with an isotype control antibody. The assay was done 
  according to the manufacturer’s instructions.
The following oligonucleotide pairs were used: 5–NF-κB, 5′-C  C  C  C  T-
C  C  A  C  T  G  C  C  A  A  G  C  A  C  A  G  C   and 3–NF-κB, 5′- G C  C  C  C  C  A  T  C  C  T  C  C  T-
T  C  T  T  C  C  T  C   to amplify a 354-bp region of the AID promoter surrounding 
the NF-κB binding site and 5-APO, 5′-G  C  C  C  A  A  T  G  T  G  G  G  T  G  G  T  G  C  -
C  A  C  -3′ and 3-APO, 5′-CTCAGATTTGAGATCATTCTCTCCAAG to 
amplify a 313-bp region of the APOBEC1 promoter, which includes an 
APOBEC1-specifi  c NF-κB binding site. PCR amplifi  cation reactions 
within the linear range were loaded onto agarose gels that were subsequently 
stained with SyBR green dye (Molecular Probes) and visualized using a 
  Typhoon Fluor Imager.
NF-𝗋B luciferase reporter assays. For NF-κB luciferase reporter assays, 
we constructed replication-defi  cient retroviral constructs carrying the fi  re-
fl  y luciferase gene downstream the AID promoter region (nucleotides 
–1500 to –1) with the κB binding site intact (Fig. 5 B, wt κB Luc) or 
  mutated (Fig. 5 B, mut κB Luc). These constructs were transfected into 
293T cells to produce two varieties of murine stem cell virus–red virus, 
which were used to infect bone marrow cells in the presence or absence of 
Ab-MLV.
7 d after infection, cells were harvested and resuspended in PBS buff  er 
with a proteinase inhibitor mixture (Sigma-Aldrich). Luciferase activity 
was determined by using the Promega luciferase assay kit on cell lysates 
(which were prepared as per the manufacturer’s instructions). Lumines-
cence was read on a Wallac 1450 Microbeta Trilux luminometer. Protein 
concentration in lysates was determined by Bradford protein assay (Bio-
Rad Laboratories).
We wish to thank Naomi Rosenberg for reagents and valuable discussions, David Levy 
for Ifnar−/− mice, and Eva Besmer for helpful comments on the manuscript.
This work has been supported in part by a grant from the National Institutes of 
Health, by the Keck Foundation, and by The Rockefeller University.
The authors have no confl  icting fi  nancial interests.
Submitted: 22 August 2006
Accepted: 29 December 2006
REFERENCES
 1. Ramiro, A.R., M. Jankovic, T. Eisenreich, S. Difi  lippantonio,  S. 
Chen-Kiang, M. Muramatsu, T. Honjo, A. Nussenzweig, and M.C. 
Nussenzweig. 2004. AID is required for c-myc/IgH chromosome trans-
locations in vivo. Cell. 118:431–438.
 2. Okazaki, I.M., H. Hiai, N. Kakazu, S. Yamada, M. Muramatsu, K. 
Kinoshita, and T. Honjo. 2003. Constitutive expression of AID leads to 
tumorigenesis. J. Exp. Med. 197:1173–1181.
  3.  Sayegh, C.E., M.W. Quong, Y. Agata, and C. Murre. 2003. E-proteins 
directly regulate expression of activation-induced deaminase in mature 
B cells. Nat. Immunol. 4:586–593.
 4. Dedeoglu, F., B. Horwitz, J. Chaudhuri, F.W. Alt, and R.S. Geha. 
2004. Induction of activation-induced cytidine deaminase gene expres-
sion by IL-4 and CD40 ligation is dependent on STAT6 and NFkappaB. 
Int. Immunol. 16:395–404.
 5. Gonda, H., M. Sugai, Y. Nambu, T. Katakai, Y. Agata, K.J. Mori, Y. 
Yokota, and A. Shimizu. 2003. The balance between Pax5 and Id2 activ-
ities is the key to AID gene expression. J. Exp. Med. 198:1427–1437.
 6. Pasqualucci, L., Y. Kitaura, H. Gu, and R. Dalla-Favera. 2006. PKA-
mediated phosphorylation regulates the function of activation-induced 
deaminase (AID) in B cells. Proc. Natl. Acad. Sci. USA. 103:395–400.
 7. Chaudhuri, J., C. Khuong, and F.W. Alt. 2004. Replication protein A 
interacts with AID to promote deamination of somatic hypermutation 
targets. Nature. 430:992–998.
 8. Basu, U., J. Chaudhuri, C. Alpert, S. Dutt, S. Ranganath, G. Li, J.P. 
Schrum, J.P. Manis, and F.W. Alt. 2005. The AID antibody diversifi  ca-
tion enzyme is regulated by protein kinase A phosphorylation. Nature. 
438:508–511.
 9. McBride, K.M., A. Gazumyan, E.M. Woo, V.M. Barreto, D.F. 
Robbiani, B.T. Chait, and M.C. Nussenzweig. 2006. Regulation of 
hypermutation by activation-induced cytidine deaminase phosphorylation. 
Proc. Natl. Acad. Sci. USA. 103:8798–8803.
10. McBride, K.M., V. Barreto, A.R. Ramiro, P. Stavropoulos, and M.C. 
Nussenzweig. 2004. Somatic hypermutation is limited by CRM1-
  dependent nuclear export of activation-induced deaminase. J. Exp. Med. 
199:1235–1244.
11. Ito, S., H. Nagaoka, R. Shinkura, N. Begum, M. Muramatsu, M. 
Nakata, and T. Honjo. 2004. Activation-induced cytidine deami-
nase shuttles between nucleus and cytoplasm like apolipoprotein B 
mRNA editing catalytic polypeptide 1. Proc. Natl. Acad. Sci. USA. 
101:1975–1980.
12.  Brar, S.S., M. Watson, and M. Diaz. 2004. Activation-induced cytosine 
deaminase (AID) is actively exported out of the nucleus but retained by 
the induction of DNA breaks. J. Biol. Chem. 279:26395–26401.
13. Machida, K., K.T. Cheng, V.M. Sung, S. Shimodaira, K.L. Lindsay, 
A.M. Levine, M.Y. Lai, and M.M. Lai. 2004. Hepatitis C virus induces 
a mutator phenotype: enhanced mutations of immunoglobulin and pro-
tooncogenes. Proc. Natl. Acad. Sci. USA. 101:4262–4267.
14.  Uchida, J., T. Yasui, Y. Takaoka-Shichijo, M. Muraoka, W. Kulwichit, 
N. Raab-Traub, and H. Kikutani. 1999. Mimicry of CD40 sig-
nals by Epstein-Barr virus LMP1 in B lymphocyte responses. Science. 
286:300–303.
15. Tobollik, S., L. Meyer, M. Buettner, S. Klemmer, B. Kempkes, E. 
Kremmer, G. Niedobitek, and B. Jungnickel. 2006. Epstein-Barr-virus 
nuclear antigen 2 inhibits AID expression during EBV-driven B-cell 
growth. Blood. 108:3859–3864.
16. He, B., X. Qiao, and A. Cerutti. 2004. CpG DNA induces IgG class 
switch DNA recombination by activating human B cells through an in-
nate pathway that requires TLR9 and cooperates with IL-10. J. Immunol. 
173:4479–4491.
17. Sha, W.C., H.C. Liou, E.I. Tuomanen, and D. Baltimore. 1995. 
Targeted disruption of the p50 subunit of NF-kappa B leads to multi-
focal defects in immune responses. Cell. 80:321–330.
18.  Bhattacharya, D., D.U. Lee, and W.C. Sha. 2002. Regulation of Ig class 
switch recombination by NF-kappaB: retroviral expression of RelB in 
activated B cells inhibits switching to IgG1, but not to IgE. Int. Immunol. 
14:983–991.
19. He, B., N. Raab-Traub, P. Casali, and A. Cerutti. 2003. EBV-encoded 
latent membrane protein 1 cooperates with BAFF/BLyS and APRIL to 
induce T cell-independent Ig heavy chain class switching. J. Immunol. 
171:5215–5224.
20.  Gourzi, P., T. Leonova, and F.N. Papavasiliou. 2006. A role for activation-
induced cytidine deaminase in the host response against a transforming 
retrovirus. Immunity. 24:779–786.JEM VOL. 204, February 19, 2007  265
BRIEF DEFINITIVE REPORT
21.  Kawai, T., and S. Akira. 2006. Innate immune recognition of viral 
  infection. Nat. Immunol. 7:131–137.
22. Takeda, K., and S. Akira. 2004. TLR signaling pathways. Semin. 
Immunol. 16:3–9.
23. Pasare, C., and R. Medzhitov. 2005. Control of B-cell responses by 
Toll-like receptors. Nature. 438:364–368.
24.  Gavin, A.L., K. Hoebe, B. Duong, T. Ota, C. Martin, B. Beutler, and 
D. Nemazee. 2006. Adjuvant-enhanced antibody responses in the 
  absence of toll-like receptor signaling. Science. 314:1936–1938. 
25.  Honda, K., H. Yanai, A. Takaoka, and T. Taniguchi. 2005. Regulation of 
the type I IFN induction: a current view. Int. Immunol. 17:1367–1378.
26.  Nakamura, Y., R.J. Grumont, and S. Gerondakis. 2002. NF-kappaB1 can 
inhibit v-Abl-induced lymphoid transformation by functioning as a neg-
ative regulator of cyclin D1 expression. Mol. Cell. Biol. 22:5563–5574.
27. Kenter, A.L., R. Wuerff  el, C. Dominguez, A. Shanmugam, and H. 
Zhang. 2004. Mapping of a functional recombination motif that defi  nes 
isotype specifi  city for mu→gamma3 switch recombination implicates 
NF-kappaB p50 as the isotype-specifi  c switching factor. J. Exp. Med. 
199:617–627.
28.  Rosenberg, N., and D. Baltimore. 1976. A quantitative assay for trans-
formation of bone marrow cells by Abelson murine leukemia virus. 
J. Exp. Med. 143:1453–1463.